Zynerba Pharmaceuticals (ZYNE) stock is up 53.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 67 out of a possible 100.
That score is mainly influenced by a long-term technical score of 83. ZYNE’s score also includes a fundamental score of 69. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $21.25. This means analysts expect the stock to add 73.33% over the next 12 months. The short-term technical score for ZYNE is 48.
What’s Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock has risen 13.52% while the S&P 500 is up 0.23% as of 12:47 PM on Monday, Jul 22. ZYNE is up $1.46 from the previous closing price of $10.80 on volume of 1,834,186 shares. Over the past year the S&P 500 is up 6.29% while ZYNE is up 53.44%. ZYNE lost -$2.61 per share in the over the last 12 months.